Apalutamide in Metastatic Castration-Sensitive Prostate Cancer (mCSPC): A Case-Based Discussion
Release Date: 05/31/2024
New Roles, Real Talk: Urology, Identity and LGBTQ+ Voices
AUANews Inside Tract
In this episode of AUA Inside Tract, join fellow Dr. Andrew Lai and newly minted attending Dr. Rabun Jones as they reflect on life after residency, tackling imposter syndrome and the challenges of stepping into new roles. They also share personal perspectives on LGBTQ+ representation and the evolving culture of acceptance in medicine.
info_outline
SAU/AUA Urology Match Insider: What You Need to Know Part 1
AUANews Inside Tract
Developed by the Society of Academic Urologists in partnership with the American Urological Association, the SAU/AUA Urology Match Insider series provides medical students interested in the field of urology an inside look into the Urology Residency Match process. In part 1 of this episode, medical student, Vivian Wang, sits down with Dr. Gina Badalato and Dr. Erica Traxel to discuss what students need to know about the Match, including timeline, dos and don’ts for applicants and what to expect during the process.
info_outline
Inside Men’s Health: A Clinician’s View
AUANews Inside Tract
In this episode of AUA Inside Tract, join Dr. Petar Bajic, director of Men's Health, and Dr. Raevti Bole, Men's Health specialist, from the Cleveland Clinic as they share clinical insights and real-world perspectives on men’s health. From prevention to patient care, this episode highlights what clinicians need to know during Men’s Health Month.
info_outline
Physician Scientist - Different Paths to Success
AUANews Inside Tract
The Physician Scientist - Different Paths to Success Webinar was held on May 20, 2025. This webinar highlighted the diverse experiences of our panelists and showcased the multiple career trajectories available to physician-scientists in urology.
info_outline
Urology Spotlight Series: Andrology/Men’s Health
AUANews Inside Tract
Developed by the Medical Student Membership Workgroup, the Urology Spotlight Series educates medical students about a particular subspecialty within urology, including common cases and procedures. In this episode, Daniela Orozco-Rendon, medical student at Geisel School of Medicine at Dartmouth, is joined by Dr. Mohit Khera, Professor of Urology and F. Brantley Scott Chair in Urology at Baylor College of Medicine, for a discussion on the field of Andrology/Men’s Health.
info_outline
AUA Census Trends: Why Urologists are Choosing Fellowships
AUANews Inside Tract
In this episode, Dr. Amanda North, Chief of Pediatric Urology at Children's Hospital at Montefiore Einstein, joins Dr. Susan MacDonald, Program Director at Penn State, for a deep dive into fellowship training trends in urology. Using AUA census data, they explore generational shifts, gender disparities and evolving motivations for pursuing fellowships. From the growing percentage of women in the field to the increasing complexity of urologic care, they discuss how patient expectations, academic aspirations and practice models are reshaping the specialty. The 2025 AUA Census is now open. Visit...
info_outline
Urology Spotlight Series: Genitourinary Reconstruction
AUANews Inside Tract
Developed by the Medical Student Membership Workgroup, the Urology Spotlight Series educates medical students about a particular subspecialty within urology, including common cases and procedures. In this episode, medical student, Jake Ratanawong, is joined by Dr. Sean Elliott, Professor and Director of Reconstructive Urology at the University of Minnesota, for a discussion on the field of Genitourinary Reconstruction.
info_outline
Navigating the Urology Team: The APP - Physician Dynamic
AUANews Inside Tract
In the fast-paced world of urology, collaboration is key to delivering optimal patient care. Navigating the Urology Team: The APP-Physician Dynamic explores the crucial partnership between Advanced Practice Providers (APPs) and Physicians. This insightful guide delves into how these two roles complement each other, fostering teamwork, enhancing patient outcomes and streamlining clinical workflows. Whether you are a physician or an APP, understanding the unique strengths each brings to the table is vital for building an efficient, patient-centered team.
info_outline
Legislating Urology: The AUA & Advocacy Efforts
AUANews Inside Tract
Join Dr. Andrew Harris and the AUA's Vice President of Legislative and Political Affairs, Brad Stine, as they talk about urologic advocacy, the AUA Summit and how the AUA is involved in legislative affairs.
info_outline
Advancing Prostate Cancer Diagnosis with High-Quality Prostate MR Images
AUANews Inside Tract
Join Dr. Matt Nielsen, Chair of AUA’s Science and Quality Council and Chair of the Department of Urology at University of North Carolina Chapel Hill as he speaks with Dr. Andrei Purysko, Section Head of Abdominal Imaging at the Cleveland Clinic and Physician Leader of the American College of Radiology’s Prostate MR Image Quality Improvement Collaborative, on improving the diagnosis of clinically significant prostate cancer with the use of high-quality prostate MR images. For additional information, please visit AUAnet.org/QISummit.
info_outlineThis podcast “Apalutamide in Metastatic Castration-Sensitive Prostate Cancer (mCSPC): A Case-Based Discussion” was originally presented as an AUA newsworthy webinar and contains data regarding the clinical efficacy and safety of apalutamide. It is presented on behalf of Janssen and is not certified for CME; speakers were compensated. For full details, see the video webinar here.
TITAN, a Phase 3 double-blind study, randomized patients with metastatic castration-sensitive prostate cancer (mCSPC) to apalutamide (Apa; 240 mg oral once daily) + androgen deprivation therapy (ADT; n=525) or placebo + ADT (n=527).1,2 All patients received a concomitant gonadotropin-releasing hormone analog or had prior bilateral orchiectomy.3 Patients who received prior treatment for localized disease or received but did not progress on docetaxel were permitted. Dual primary endpoints were radiographic progression-free survival and overall survival (OS).1,2
At primary analysis (median follow-up: 22.7 months), Apa + ADT reduced the risk of radiographic progression or death by 52% vs placebo + ADT (HR: 0.48; 95% CI: 0.39–0.60). Apa + ADT also reduced the risk of death by 33% vs placebo + ADT (HR: 0.67; 95% CI: 0.51–0.89).1 At primary analysis cutoff, TITAN was unblinded and 39.5% of patients who received placebo + ADT crossed over to receive Apa + ADT; these patients were analyzed as part of the placebo + ADT population in the intent-to-treat analyses. The IPCW log-rank test was performed to account for crossover and showed a 48% reduction in the risk of death for Apa + ADT vs placebo + ADT (HR: 0.52; 95% CI: 0.42–0.64). At final analysis (median follow-up: 44.0 months), Apa + ADT reduced the risk of death by 35% vs placebo + ADT (median OS: NE vs 52.2 months; HR: 0.65; 95% CI: 0.53–0.79).
In a prespecified subgroup analysis, Apa + ADT improved OS vs placebo + ADT, regardless of disease volume. In patients with high-volume disease, Apa + ADT reduced the risk of death by 30% vs placebo + ADT (HR: 0.70; 95% CI: 0.56–0.88); for low-volume disease, Apa + ADT reduced the risk of death by 48% vs placebo + ADT (HR: 0.52; 95% CI: 0.35–0.79).2
The following post hoc analyses data are not included in the full ERLEADA® (apalutamide) Prescribing Information.
Post hoc exploratory analyses investigated PSA kinetics.4,5 After 3 months of Apa treatment, median OS was not reached in patients with a PSA response. In patients without a PSA response, median OS was 37.7 months.5 Most Apa + ADT-treated patients had undetectable PSA at 3 months. By 12 months, 64% of Apa-treated patients had undetectable PSA vs 23% of patients treated with placebo + ADT.5
Please see the full Prescribing Information for ERLEADA® (apalutamide) at www.erleadahcp.com.
- Chi KN, et al. N Engl J Med. 2019;381:13–24.
- Chi KN, et al. J Clin Oncol. 2021;39:2294–2303.
- ERLEADA® (apalutamide) [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.
- Chowdhury S, et al. Ann Oncol. 2023;34:477–485.
- Chi KN, et al. Presented at AUA; September 10–13, 2021; Las Vegas, Nevada.